 |
|
Doxorubicin in Treatment of Malignant Solid Tumors in Children
Charles B. Pratt, MD;
Ellen C. Shanks, RN
Am J Dis Child. 1974;127(4):534-536.
Abstract
Doxorubicin (adriamycin) was administered to 35 children with malignant solid tumors to further evaluate its usefulness and toxicity. Two dosage schedules were used: 25 mg/sq m of body surface area weekly, and 25 mg/sq m on two consecutive days and then every two weeks. The agent produced tumor regression in 17 children; the tumors included osteosarcoma, neuroblastoma, Wilms tumor, reticulum cell (histiocytic) lymphoma, and hepatoblastoma. Toxic reactions including alopecia, hematopoietic depression, vomiting, mucosal ulcerations, and weight loss were similar with each schedule. Administration of doxorubicin in a dosage of 50 mg/sq m at two-week intervals allows time for detection of toxic reactions and evaluation of tumor response before administration of subsequent doses.
Author Affiliations
Memphis
From the Chemotherapy Service, St. Jude Children's Research Hospital, Memphis.
Footnotes
Received for publication Oct 18, 1973; accepted Nov 27.
Reprint requests to St. Jude Children's Research Hospital, 332 N Lauderdale, PO Box 318, Memphis, TN 38103 (Dr. Pratt).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina et al.
The Oncologist 2004;9:422-441.
ABSTRACT
| FULL TEXT
Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial
Goorin et al.
JCO 2002;20:426-433.
ABSTRACT
| FULL TEXT
Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial
Meyer et al.
JCO 2001;19:171-182.
ABSTRACT
| FULL TEXT
|
